Package Leaflet: Information for the User
Voriconazole Fosun Pharma 200 mg powder for solution for infusion EFG
Voriconazole
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
This medicine contains the active substance voriconazole. Voriconazole is an antifungal medicine. It works by killing or preventing the growth of fungi that cause infections.
It is used for the treatment of patients (adults and children aged 2 years or older) with:
Voriconazole Fosun Pharma is used in patients with serious fungal infections that can be life-threatening.
Prevention of fungal infections in bone marrow transplant recipients with high risk.
This medicine should only be used under medical supervision.
Do not use Voriconazole Fosun Pharma:
It is very important that you inform your doctor or pharmacist if you are using or have recently used other medicines, including those obtained without a prescription, or herbal remedies.
During treatment with voriconazole, you must not take the following medicines:
Warnings and precautions
Consult your doctor or nurse before starting to take Voriconazole Fosun Pharma if:
You should avoid any exposure to the sun and sunlight during treatment. It is important that you cover exposed areas and use a sunscreen with a high sun protection factor (SPF), as you may have increased skin sensitivity to the sun's UV rays. These precautions also apply to children.
While you are being treated with Voriconazole Fosun Pharma:
sunburn
severe skin rash or blisters
bone pain
If you develop skin disorders such as those described above, your doctor may refer you to a dermatologist who, after consultation, may consider it important for you to be examined regularly. There is a small probability that you may develop skin cancer with long-term use of this medicine.
If you develop signs of "adrenal insufficiency" in which the adrenal glands do not produce adequate amounts of certain steroid hormones, such as cortisol, which can cause symptoms such as chronic or prolonged fatigue, muscle weakness, loss of appetite, weight loss, and abdominal pain, inform your doctor.
Your doctor should monitor your liver and kidney function by performing blood tests.
Children and adolescents
This medicine must not be given to children under 2 years of age.
Other medicines and Voriconazole Fosun Pharma 200 mg
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription.
Some medicines, when used at the same time as voriconazole, can affect the action of this medicine or voriconazole may affect the action of other medicines.
Tell your doctor if you are using the following medicine, as simultaneous treatment with voriconazole should be avoided if possible:
Tell your doctor if you are using any of the following medicines, as simultaneous treatment with voriconazole should be avoided as much as possible, and a dose adjustment of voriconazole may be necessary:
Tell your doctor if you are taking any of the following medicines, as you may need a dose adjustment or monitoring to check that these medicines and/or voriconazole are still working as expected:
Pregnancy and breast-feeding
Do not use this medicine during pregnancy unless your doctor has told you to. Women of childbearing age should use effective contraception. Contact your doctor immediately if you become pregnant during treatment with this medicine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
This medicine may cause blurred vision or discomfort due to increased sensitivity to light. If this happens, do not drive or use tools or machines and tell your doctor.
Voriconazole Fosun Pharma contains sodium and cyclodextrin
This medicine contains 217.6 mg of sodium (the main component of cooking/table salt) in each vial. This is equivalent to 11% of the maximum recommended daily intake of sodium for an adult.
This medicine contains sulfobutyl ether beta-cyclodextrin sodium. Each vial contains 3.2 g of sulfobutyl ether beta-cyclodextrin sodium. If you have kidney disease, consult your doctor before taking this medicine.
Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again.
Your doctor will determine the dose based on your weight and the type of infection you have.
The recommended dose in adults (including elderly patients) is as follows:
Intravenous infusion | |
Dose during the first 24 hours (Loading dose) | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours (Maintenance dose) | 4 mg/kg twice daily |
Depending on your response to treatment, your doctor may reduce the dose to 3 mg/kg twice daily.
Your doctor may reduce the dose if you have mild to moderate cirrhosis.
Use in children and adolescents
The recommended dose in children and adolescents is as follows:
Intravenous infusion | ||
Children aged 2 to less than 12 years and adolescents aged 12 to 14 years who weigh less than 50 kg | Adolescents aged 12 to 14 years who weigh 50 kg or more and all adolescents over 14 years | |
Dose during the first 24 hours (Loading dose) | 9 mg/kg every 12 hours during the first 24 hours | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours (Maintenance dose) | 8 mg/kg twice daily | 4 mg/kg twice daily |
Depending on your response to treatment, your doctor may increase or decrease the daily dose.
This medicine must be reconstituted and diluted to the correct concentration by hospital pharmacy or nursing staff (for more information, see the end of this leaflet).
It will be administered by intravenous infusion (into a vein) at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.
If you or your child are using this medicine to prevent fungal infections, your doctor may stop the administration of voriconazole if you or your child experience treatment-related side effects.
This medicine must not be given to children under 2 years of age.
If you miss a dose of Voriconazole Fosun Pharma
Given that you will receive this medicine under close medical supervision, it is unlikely that you will miss a dose. However, tell your doctor or pharmacist if you think you have missed a dose.
If you are given more Voriconazole Fosun Pharma than you should
Given that you will receive this medicine under close medical supervision, it is unlikely that you will receive more doses than you should. However, tell your doctor or pharmacist if you think you have received more than you should.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you stop treatment with Voriconazole Fosun Pharma
Treatment with this medicine should be continued for as long as your doctor considers necessary, however, the duration of treatment with this medicine should not exceed 6 months.
Patient with compromised immune system or those with complicated infections may require longer treatments to prevent the infection from coming back. Once your condition improves, intravenous infusion may be replaced by oral tablets.
When your doctor stops treatment with this medicine, you should not experience any effects from stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If any appear, it is most likely to be mild and transient. However, some may be serious and require medical attention.
Severe Adverse Effects–Stop using this medicine and consult your doctor immediately
Other Adverse Effects
Very frequent: may affect more than 1 in 10 people
Frequent: may affect up to 1 in 10 people
Infrequent: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Adverse effects of unknown frequency (frequency cannot be estimated from available data):
Other important adverse effects whose frequency is unknown, but which should be reported to the doctor immediately:
During infusion, infrequently, there have been reactions with this medicine (including facial redness, fever, sweating, increased heart rate, and difficulty breathing). The doctor may interrupt the infusion if this occurs.
Since it has been observed that this medicine affects the liver and kidneys, your doctor should monitor liver and kidney function through blood tests. Inform your doctor if you have stomach pain or if the stools have a different consistency.
Cases of skin cancer have been reported in patients treated with this medicine for long periods.
The frequency of sunburn or severe skin reactions after exposure to light or sun was higher in children. If you or your child have skin disorders, your doctor may refer you to a dermatologist who, after consultation, may decide that it is important for you or your child to undergo regular follow-up. Elevated liver enzymes were also observed more frequently in children.
If any of these adverse effects persist or are bothersome, inform your doctor.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Store below 25°C.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the label and carton. The expiration date is the last day of the month indicated.
Chemical and physical stability in use has been demonstrated for 24 hours between 2°C and 8°C.
From a microbiological point of view, unless the opening method excludes the risk of microbial contamination, the reconstituted solution should be used immediately. If not used immediately, the storage times and conditions are the responsibility of the user.
This reconstituted medicine must be diluted first with a compatible infusion diluent before being administered (for more information, see the end of this leaflet).
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Voriconazol Fosun Pharma
Each vial contains 200 mg of voriconazole, equivalent to a concentrated solution of 10 mg/ml once reconstituted following the instructions indicated by the hospital pharmacy or nursing staff (see information at the end of this leaflet).
Appearance of the Product and Package Contents
Voriconazol Fosun Pharma 200 mg is presented in single-use glass vials in the form of a white lyophilized cake or powder for solution for infusion. Voriconazol Fosun Pharma 200 mg powder for solution for infusion is available in a carton box containing 1 vial.
Marketing Authorization Holder and Manufacturer
Fosun Pharma Sp. z o.o.
Zajecza 15, Warsaw (00-351), Poland
This medicine is authorized in the Member States of the European Economic Area under the following names:
Austria: Voriconazol Fosun Pharma
Belgium: Voriconazol Fosun Pharma 200 mg Pulver zur Herstellung einer Infusionslösung
Voriconazol Fosun Pharma 200 mg poeder voor oplossing voor infusie
Voriconazol Fosun Pharma 200 mg poudre pour solution pour perfusion
Germany: Voriconazol Fosun Pharma 200 mg Pulver zur Herstellung einer Infusionslösung
France: Voriconazole Fosun Pharma
Italy: Voriconazolo Fosun Pharma
Netherlands: Voriconazol Fosun Pharma
Poland: Voriconazole Fosun Pharma
Portugal: Voriconazole Fosun Pharma
Spain: Voriconazol Fosun Pharma
Date of the Last Revision of this Leaflet:August 2021
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Voriconazol Fosun Pharma 200 mg powder for solution for infusion:
Volumes of Voriconazol Fosun Pharma 200 mg Concentrate 10 mg/ml Required
Body Weight (kg) | Volume of Voriconazol Fosun Pharma 200 mg Concentrate (10 mg/ml) Required for: | ||||
Dose of 3 mg/kg (number of vials) | Dose of 4 mg/kg (number of vials) | Dose of 6 mg/kg (number of vials) | Dose of 8 mg/kg (number of vials) | Dose of 9 mg/kg (number of vials) | |
10 | - | 4.0 ml (1) | - | 8.0 ml (1) | 9.0 ml (1) |
15 | - | 6.0 ml (1) | - | 12.0 ml (1) | 13.5 ml (1) |
20 | - | 8.0 ml (1) | - | 16.0 ml (1) | 18.0 ml (1) |
25 | - | 10.0 ml (1) | - | 20.0 ml (1) | 22.5 ml (2) |
30 | 9.0 ml (1) | 12.0 ml (1) | 18.0 ml (1) | 24.0 ml (2) | 27.0 ml (2) |
35 | 10.5 ml (1) | 14.0 ml (1) | 21.0 ml (2) | 28.0 ml (2) | 31.5 ml (2) |
40 | 12.0 ml (1) | 16.0 ml (1) | 24.0 ml (2) | 32.0 ml (2) | 36.0 ml (2) |
45 | 13.5 ml (1) | 18.0 ml (1) | 27.0 ml (2) | 36.0 ml (2) | 40.5 ml (3) |
50 | 15.0 ml (1) | 20.0 ml (1) | 30.0 ml (2) | 40.0 ml (2) | 45.0 ml (3) |
55 | 16.5 ml (1) | 22.0 ml (2) | 33.0 ml (2) | 44.0 ml (3) | 49.5 ml (3) |
60 | 18.0 ml (1) | 24.0 ml (2) | 36.0 ml (2) | 48.0 ml (3) | 54.0 ml (3) |
65 | 19.5 ml (1) | 26.0 ml (2) | 39.0 ml (2) | 52.0 ml (3) | 58.5 ml (3) |
70 | 21.0 ml (2) | 28.0 ml (2) | 42.0 ml (3) | - | - |
75 | 22.5 ml (2) | 30.0 ml (2) | 45.0 ml (3) | - | - |
80 | 24.0 ml (2) | 32.0 ml (2) | 48.0 ml (3) | - | - |
85 | 25.5 ml (2) | 34.0 ml (2) | 51.0 ml (3) | - | - |
90 | 27.0 ml (2) | 36.0 ml (2) | 54.0 ml (3) | - | - |
95 | 28.5 ml (2) | 38.0 ml (2) | 57.0 ml (3) | - | - |
100 | 30.0 ml (2) | 40.0 ml (2) | 60.0 ml (3) | - | - |
Voriconazol Fosun Pharma is a sterile, preservative-free, single-dose lyophilized powder.
Therefore, from a microbiological point of view, the solution should be used immediately once reconstituted. If not used immediately, the storage time and conditions before use are the responsibility of the user.
Compatible Infusion Solutions:
The reconstituted solution can be diluted with:
Sodium chloride 9 mg/ml (0.9%) injection solution
Compound sodium lactate intravenous infusion
5% glucose solution and lactated Ringer's solution for intravenous infusion
5% glucose solution and 0.45% sodium chloride solution for intravenous infusion
5% glucose solution for intravenous infusion
5% glucose solution with 20 mEq of potassium chloride for intravenous infusion
0.45% sodium chloride solution for intravenous infusion
5% glucose solution and 0.9% sodium chloride solution for intravenous infusion
The compatibility of voriconazole with other diluents different from those specifically mentioned above (or those mentioned below in "Incompatibilities") is unknown.
Incompatibilities
This medicine should not be infused in the same vein or cannula simultaneously with other drug infusions, including parenteral nutrition (e.g., Aminofusin 10% Plus).
Hemoderivatives should not be infused simultaneously with the administration of this medicine.
Total parenteral nutrition can be infused simultaneously with the administration of this medicine, but not in the same vein or cannula.
This medicine should not be diluted with 4.2% sodium bicarbonate solution.